Indonesia says to secure Sinopharm COVID-19 vaccine for private use

BPOM did not respond to a request for comment. At the same forum, State-owned enterprises minister Erick Thohir said more than 6,600 companies had signed up for the private scheme, which some health experts have criticised because of concern it could worsen vaccine inequity.

Reuters | Jakarta | Updated: 25-02-2021 11:07 IST | Created: 25-02-2021 11:07 IST
Indonesia says to secure Sinopharm COVID-19 vaccine for private use

Indonesia will receive at least two million doses of a coronavirus vaccine produced by China's Sinopharm for use in a private vaccination scheme due to run alongside a national inoculation programme, a minister said on Thursday. Indonesia, which has faced one of the biggest COVID-19 outbreaks in Asia, aims to vaccinate 181.5 million people within about a year using vaccines made by companies such as Sinovac Biotech, Novavax and AstraZeneca.

Luhut Binsar Pandjaitan, Indonesia's minister for maritime affairs and investment, said the China National Pharmaceutical Group (Sinopharm) vaccine would be part of the private scheme. "What's fixed is two million (doses). Three million is our hope...we will vaccinate employees in stages," he told an economic forum.

The private plan has been pushed by Indonesian business as a way for companies to buy vaccines from the government so that their employees can be vaccinated in order to help prop up the country's battered economy. The private plan is due to use alternative vaccines from the ones currently being used and the government is preparing a regulation.

Bambang Heriyanto, corporate secretary of Bio Farma, a state-owned pharmaceutical company in charge of procuring vaccines, said talks were still ongoing with Sinopharm and the vaccine needed approval from the food and drugs agency (BPOM). BPOM did not respond to a request for comment.

At the same forum, State-owned enterprises minister Erick Thohir said more than 6,600 companies had signed up for the private scheme, which some health experts have criticised because of concern it could worsen vaccine inequity. Sinopharm did not immediately respond to a request for comment.

Sinopharm affiliate, the Wuhan Institute Of Biological Products, said on Wednesday its vaccine had an efficacy rate of 72.51% against COVID-19, citing interim analysis of late-stage clinical trial data, without offering more details.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


TRENDING

OPINION / BLOG / INTERVIEW

Viral variants and vaccine nationalism pose two-pronged threat to Covid victory

... ...

Tracking Fintech during COVID-19: Harnessing power of technology

Its abundantly clear now that as fintech cements its place in the financial sector, accelerated further by the COVID-19 pandemic, it could open the sector to new possibilities by harnessing the power of technology to deliver financial ...

Tectonic turns: How technology shaped healthcare over the decades

Tracing an episodic evolution, with technology at the interface of human and his health....

World Water Day sees crises of inequality in countries both rich and poor

... ...

Videos

Latest News

Delhi Minister Kailash Gahlot tests positive for COVID-19

Delhi Transport Minister Kailash Gahlot on Wednesday informed that he has tested positive for COVID-19. He informed that he has isolated himself and urged those who came in contact with him recently to take necessary precautions.I have test...

China shares end higher as some IT firms pledge against anti-competition

China shares rose on Wednesday, with IT firms leading the gains, as investors cheered internet platform companies pledging to avoid anti-competitive behaviours after e-commerce giant Alibaba was fined a record 2.75 billion last week for suc...

To Accelerate Coding Literacy across India, StayQrious Launches India's First Kid-friendly Coding Course for Free Online

New Delhi, Delhi, India NewsVoir The course has been created by Indias most trusted instructors with visual explanations that deepen a childs intuition for the concepts. Created according to the global CSTA standards, the course is a uniqu...

Delhi minister tests positive for COVID-19

Delhi Transport minister Kailash Gahlot on Wednesday said he has tested positive for COVID-19, and advised those who came in contact with him to take necessary precautions.The minister was administered the first dose of the COVID-19 vaccine...

Give Feedback